Published in Hum Vaccin Immunother on June 18, 2013
Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part I: Overview, vaccines for enteric viruses and Vibrio cholerae. Hum Vaccin Immunother (2015) 0.86
Immune responses elicited against rotavirus middle layer protein VP6 inhibit viral replication in vitro and in vivo. Hum Vaccin Immunother (2014) 0.83
Protection against live rotavirus challenge in mice induced by parenteral and mucosal delivery of VP6 subunit rotavirus vaccine. Arch Virol (2015) 0.80
Rotavirus capsid VP6 tubular and spherical nanostructures act as local adjuvants when co-delivered with norovirus VLPs. Clin Exp Immunol (2017) 0.76
Rotavirus capsid VP6 protein acts as an adjuvant in vivo for norovirus virus-like particles in a combination vaccine. Hum Vaccin Immunother (2016) 0.76
The Replacement of 10 Non-Conserved Residues in the Core Protein of JFH-1 Hepatitis C Virus Improves Its Assembly and Secretion. PLoS One (2015) 0.76
A new rotavirus VP6-based foreign epitope presenting vector and immunoreactivity of VP4 epitope chimeric proteins. Viral Immunol (2014) 0.75
Rotavirus Recombinant VP6 Nanotubes Act as an Immunomodulator and Delivery Vehicle for Norovirus Virus-Like Particles. J Immunol Res (2016) 0.75
Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med (2006) 11.49
Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med (2006) 9.93
Lymphokine control of in vivo immunoglobulin isotype selection. Annu Rev Immunol (1990) 7.93
Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med (2012) 4.74
Three-dimensional structure of rotavirus. J Mol Biol (1988) 3.79
Full genome-based classification of rotaviruses reveals a common origin between human Wa-Like and porcine rotavirus strains and human DS-1-like and bovine rotavirus strains. J Virol (2008) 3.73
The influence of antigen organization on B cell responsiveness. Science (1993) 3.32
Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity. Science (1996) 3.07
Characterization of virus-like particles produced by the expression of rotavirus capsid proteins in insect cells. J Virol (1994) 2.48
Expression of rotavirus VP2 produces empty corelike particles. J Virol (1991) 2.38
Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol (2004) 2.33
Synthesis and immunogenicity of the rotavirus major capsid antigen using a baculovirus expression system. J Virol (1987) 2.29
Preliminary characterization of an epitope involved in neutralization and cell attachment that is located on the major bovine rotavirus glycoprotein. J Virol (1985) 1.97
Rotavirus virus-like particles administered mucosally induce protective immunity. J Virol (1997) 1.96
Immunity and correlates of protection for rotavirus vaccines. Vaccine (2006) 1.73
Full genomic analysis of human rotavirus strain B4106 and lapine rotavirus strain 30/96 provides evidence for interspecies transmission. J Virol (2006) 1.61
Rotavirus vaccines: recent developments and future considerations. Nat Rev Microbiol (2007) 1.37
Antirotavirus immunoglobulin A neutralizes virus in vitro after transcytosis through epithelial cells and protects infant mice from diarrhea. J Virol (1998) 1.37
Development of an improved method for measuring neutralizing antibody to rotavirus. J Virol Methods (1991) 1.35
Comparison of the rotavirus gene 6 from different species by sequence analysis and localization of subgroup-specific epitopes using site-directed mutagenesis. Virology (1997) 1.32
CD4 T cells are the only lymphocytes needed to protect mice against rotavirus shedding after intranasal immunization with a chimeric VP6 protein and the adjuvant LT(R192G). J Virol (2002) 1.32
Structural polymorphism of the major capsid protein of rotavirus. EMBO J (2001) 1.29
Subunit rotavirus vaccine administered parenterally to rabbits induces active protective immunity. J Virol (1998) 1.23
Antibody-dependent and -independent protection following intranasal immunization of mice with rotavirus particles. J Virol (1999) 1.22
Rotavirus anti-VP6 secretory immunoglobulin A contributes to protection via intracellular neutralization but not via immune exclusion. J Virol (2006) 1.22
Antibody-independent protection against rotavirus infection of mice stimulated by intranasal immunization with chimeric VP4 or VP6 protein. J Virol (1999) 1.18
Heterologous protection induced by the inner capsid proteins of rotavirus requires transcytosis of mucosal immunoglobulins. J Virol (2002) 1.18
Protective immunity induced by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles. J Virol (1998) 1.18
Llama-derived single-chain antibody fragments directed to rotavirus VP6 protein possess broad neutralizing activity in vitro and confer protection against diarrhea in mice. J Virol (2008) 1.15
A comparison of immunogenicity of norovirus GII-4 virus-like particles and P-particles. Immunology (2012) 1.12
Protection against rotavirus infections by DNA vaccination. J Infect Dis (1996) 1.12
Norovirus VLPs and rotavirus VP6 protein as combined vaccine for childhood gastroenteritis. Vaccine (2011) 1.10
Quantification of systemic and local immune responses to individual rotavirus proteins during rotavirus infection in mice. J Clin Microbiol (1996) 1.10
Functional mapping of protective domains and epitopes in the rotavirus VP6 protein. J Virol (2000) 1.03
Migration of antigen-presenting B cells from peripheral to mucosal lymphoid tissues may induce intestinal antigen-specific IgA following parenteral immunization. J Immunol (1999) 1.02
Intranasal or oral immunization of inbred and outbred mice with murine or human rotavirus VP6 proteins protects against viral shedding after challenge with murine rotaviruses. Vaccine (2002) 0.98
Development of a Bacillus subtilis-based rotavirus vaccine. Clin Vaccine Immunol (2010) 0.98
Interference of immunoglobulin G (IgG) antibodies in IgA antibody determinations of Chlamydia pneumoniae by microimmunofluorescence test. J Clin Microbiol (1994) 0.96
Stimulation of local immunity and protection in mice by intramuscular immunization with triple- or double-layered rotavirus particles and QS-21. Virology (1998) 0.94
The antigen-limited nature of microtiter ELISAs requires partial depletion of IgG to permit reliable determination of rabbit serum IgA antibody activity. Mol Immunol (1990) 0.91
The internal rotavirus protein VP6 primes for an enhanced neutralizing antibody response. Arch Virol (2000) 0.91
Amino acid domains 280-297 of VP6 and 531-554 of VP4 are implicated in heat shock cognate protein hsc70-mediated rotavirus infection. Arch Virol (2007) 0.90
Cutting edge: limited specialization of dendritic cell subsets for MHC class II-associated presentation of viral particles. J Immunol (2009) 0.90
In vitro neutralisation of rotavirus infection by two broadly specific recombinant monovalent llama-derived antibody fragments. PLoS One (2012) 0.89
Induction of protective antiviral cytotoxic T cells by a tubular structure capable of carrying large foreign sequences. Vaccine (2002) 0.87
Serum rotavirus neutralizing-antibody titers compared by plaque reduction and enzyme-linked immunosorbent assay-based neutralization assays. J Clin Microbiol (1996) 0.85
Identification of an immunodominant CD4+ T cell epitope in the VP6 protein of rotavirus following intranasal immunization of BALB/c mice. Virology (2007) 0.84
Prime immunization with rotavirus VLP 2/6 followed by boosting with an adenovirus expressing VP6 induces protective immunization against rotavirus in mice. Virol J (2011) 0.83
Rotavirus gastroenteritis: why to back up the development of new vaccines? Comp Immunol Microbiol Infect Dis (2007) 0.82
Assembly of double-layered virus-like particles in mammalian cells by coexpression of human rotavirus VP2 and VP6. J Gen Virol (1995) 0.82
Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med (2006) 9.93
Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med (2007) 6.54
Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med (2015) 4.23
Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis (2012) 3.94
Burden of rotavirus disease in European Union countries. Pediatr Infect Dis J (2006) 2.83
Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J (2011) 2.33
Clinical efficacy of cell culture–derived and egg‐derived inactivated subunit influenza vaccines in healthy adults. Clin Infect Dis (2010) 2.16
Safety and immunogenicity of a vero cell culture-derived whole-virus influenza A(H5N1) vaccine in a pediatric population. J Infect Dis (2013) 1.64
Oral prednisolone in the acute management of children age 6 to 35 months with viral respiratory infection-induced lower airway disease: a randomized, placebo-controlled trial. J Pediatr (2003) 1.64
Major reduction of rotavirus, but not norovirus, gastroenteritis in children seen in hospital after the introduction of RotaTeq vaccine into the National Immunization Programme in Finland. Eur J Pediatr (2013) 1.29
Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life. Pediatrics (2007) 1.15
Trivalent and quadrivalent MF59(®)-adjuvanted influenza vaccine in young children: a dose- and schedule-finding study. Vaccine (2011) 1.12
A comparison of immunogenicity of norovirus GII-4 virus-like particles and P-particles. Immunology (2012) 1.12
Primary cutaneous T-cell lymphomas show a deletion or translocation affecting NAV3, the human UNC-53 homologue. Cancer Res (2005) 1.12
Norovirus VLPs and rotavirus VP6 protein as combined vaccine for childhood gastroenteritis. Vaccine (2011) 1.10
A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis. Pediatr Infect Dis J (2004) 1.10
Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines. Pediatr Infect Dis J (2009) 1.09
Intussusception after human rotavirus vaccine. Pediatr Infect Dis J (2013) 1.08
Primary versus secondary failure after varicella vaccination: implications for interval between 2 doses. Pediatr Infect Dis J (2013) 1.04
Norovirus GII-4 causes a more severe gastroenteritis than other noroviruses in young children. J Infect Dis (2011) 1.03
Efficacy of inactivated split-virus influenza vaccine against culture-confirmed influenza in healthy adults: a prospective, randomized, placebo-controlled trial. J Infect Dis (2009) 1.03
Trivalent combination vaccine induces broad heterologous immune responses to norovirus and rotavirus in mice. PLoS One (2013) 1.02
Rotavirus types in Europe and their significance for vaccination. Pediatr Infect Dis J (2006) 1.01
IL-10 gene polymorphism at -1082 A/G is associated with severe rhinovirus bronchiolitis in infants. Pediatr Pulmonol (2008) 1.00
A six-fold gradient in the incidence of type 1 diabetes at the eastern border of Finland. Ann Med (2005) 1.00
Viral etiology and incidence of acute gastroenteritis in young children attending day-care centers. Pediatr Infect Dis J (2005) 0.99
Norovirus gastroenteritis in young children receiving human rotavirus vaccine. Scand J Infect Dis (2010) 0.97
Options for the prevention of rotavirus disease other than vaccination. J Pediatr Gastroenterol Nutr (2008) 0.96
Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children. Vaccine (2009) 0.94
Cross-clade protection induced by human immunodeficiency virus-1 DNA immunogens expressing consensus sequences of multiple genes and epitopes from subtypes A, B, C, and FGH. Viral Immunol (2005) 0.94
Bordetella pertussis infection is common in nonvaccinated infants admitted for bronchiolitis. Pediatr Infect Dis J (2010) 0.92
Simultaneous presence of human herpesvirus 6 and adenovirus infections in intestinal intussusception of young children. Acta Paediatr (2012) 0.92
Noroviruses as a major cause of acute gastroenteritis in children in Finland, 2009-2010. Scand J Infect Dis (2011) 0.92
Efficacy of the pentavalent rotavirus vaccine, RotaTeq® (RV5), between doses of a 3-dose series and with less than 3 doses (incomplete regimen). Hum Vaccin (2011) 0.90
Detection of human coronaviruses in children with acute gastroenteritis. J Clin Virol (2010) 0.90
Efficacy, immunogenicity, and safety of two doses of a tetravalent rotavirus vaccine RRV-TV in Ghana with the first dose administered during the neonatal period. J Infect Dis (2013) 0.90
Vaccine-derived human-bovine double reassortant rotavirus in infants with acute gastroenteritis. Pediatr Infect Dis J (2012) 0.90
Cost-effectiveness of live-attenuated influenza vaccine, trivalent in preventing influenza in young children attending day-care centres. Vaccine (2007) 0.90
Human bocaviruses are commonly found in stools of hospitalized children without causal association to acute gastroenteritis. Eur J Pediatr (2014) 0.89
A hexavalent human rotavirus-bovine rotavirus (UK) reassortant vaccine designed for use in developing countries and delivered in a schedule with the potential to eliminate the risk of intussusception. J Infect Dis (2005) 0.89
Production and characterization of virus-like particles and the P domain protein of GII.4 norovirus. J Virol Methods (2011) 0.89
Detection of rotateq vaccine-derived, double-reassortant rotavirus in a 7-year-old child with acute gastroenteritis. Pediatr Infect Dis J (2014) 0.88
A DNA HIV-1 vaccine based on a fusion gene expressing non-structural and structural genes of consensus sequence of the A-C subtypes and the ancestor sequence of the F-H subtypes. Preclinical and clinical studies. Microbes Infect (2005) 0.87
Rotavirus. J Pediatr Gastroenterol Nutr (2008) 0.86
Gene polymorphism of IFNG +874 T/A and TLR4 +896 A/G and recurrent infections and wheezing in toddlers with history of bronchiolitis. Pediatr Infect Dis J (2009) 0.85
Varicella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccine. J Infect Dis (2013) 0.83
Immune responses elicited against rotavirus middle layer protein VP6 inhibit viral replication in vitro and in vivo. Hum Vaccin Immunother (2014) 0.83
Report of the second European expert meeting on rotavirus vaccination. Vaccine (2011) 0.82
Safety, tolerability and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in healthy young adults. Hum Vaccin (2009) 0.82
Purification of norovirus-like particles (VLPs) by ion exchange chromatography. J Virol Methods (2012) 0.82
Rotavirus gastroenteritis in Finnish children in 2006-2008, at the introduction of rotavirus vaccination. Scand J Infect Dis (2010) 0.81
Combining DNA technologies and different modes of immunization for induction of humoral and cellular anti-HIV-1 immune responses. Vaccine (2008) 0.81
Hospital bed occupancy for rotavirus and all cause acute gastroenteritis in two Finnish hospitals before and after the implementation of the national rotavirus vaccination program with RotaTeq®. BMC Health Serv Res (2014) 0.80
Safety, tolerability and immunogenicity of 15-valent pneumococcal conjugate vaccine in toddlers previously vaccinated with 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J (2015) 0.80
Protection against live rotavirus challenge in mice induced by parenteral and mucosal delivery of VP6 subunit rotavirus vaccine. Arch Virol (2015) 0.80
JC virus strains indigenous to northeastern Siberians and Canadian Inuits are unique but evolutionally related to those distributed throughout Europe and Mediterranean areas. J Mol Evol (2002) 0.79
Genetic diversity of JC virus in the Saami and the Finns: implications for their population history. Am J Phys Anthropol (2005) 0.79
Rotavirus antigenemia in children is associated with more severe clinical manifestations of acute gastroenteritis. Pediatr Infect Dis J (2014) 0.78
Pre-existing immunity to norovirus GII-4 virus-like particles does not impair de novo immune responses to norovirus GII-12 genotype. Viral Immunol (2013) 0.78
An open-label, randomized study of a 9-valent human papillomavirus vaccine given concomitantly with diphtheria, tetanus, pertussis and poliomyelitis vaccines to healthy adolescents 11-15 years of age. Pediatr Infect Dis J (2015) 0.78
Noroviruses in children seen in a hospital for acute gastroenteritis in Finland. Eur J Pediatr (2011) 0.77
Detection of vaccine-derived rotavirus strains in nonimmunocompromised children up to 3-6 months after RotaTeq® vaccination. Pediatr Infect Dis J (2015) 0.77
Genetic diversity of G1P[8] rotavirus VP7 and VP8* antigens in Finland over a 20-year period: No evidence for selection pressure by universal mass vaccination with RotaTeq® vaccine. Infect Genet Evol (2013) 0.77
GTU-MultiHIV DNA vaccine results in protection in a novel P815 tumor challenge model. Vaccine (2007) 0.76
Human bocavirus types 1, 2 and 3 in acute gastroenteritis of childhood. Acta Paediatr (2012) 0.76
Comment on the contribution by Weycker et al., "Cost of routine immunization of young children against rotavirus infection with Rotarix ® versus RotaTeq ®". Vaccine (2010) 0.75
Standardised case definitions for adverse events following immunisation - Authors' reply. Lancet (2013) 0.75
Analysis by rotavirus gene 6 reverse transcriptase-polymerase chain reaction assay of rotavirus-positive gastroenteritis cases observed during the vaccination phase of the Rotavirus Efficacy and Safety Trial (REST). Hum Vaccin Immunother (2014) 0.75
[Not Available]. Duodecim (2007) 0.75
Decrease of Rotavirus Gastroenteritis to a Low Level Without Resurgence for Five Years After Universal RotaTeq Vaccination in Finland. Pediatr Infect Dis J (2016) 0.75
[Not Available]. Duodecim (2006) 0.75
Immunization with dendritic cells transfected in vivo with HIV-1 plasmid DNA induces HIV-1-specific immune responses. Arch Virol (2011) 0.75